Lien Chia En News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Phase 2 clinical trial results of the Medigen Vaccine Biologics Corp’s COVID-19 vaccine on Wednesday were published on the Web site of <i>The Lancet: Respiratory Medicine</i>, in an early preview before publication. The study paves the way for other nations to issue emergency use authorizations or produce the Medigen vaccine, given <i>The Lancet’s</i> credibility as a highly respected medical journal with a rigorous peer-review process, Medigen’s international affairs director Lien Chia-en (連加恩) said. Lien said that the study is important as it proposes meth...

By Yang Yuan-ting, Chiu Chih-jou and Jonathan Chin / Staff reporters, with staff writerPhase 2 clinical trial results of the Medigen Vaccine Biologics Corp’s COVID-19 vaccine on Wednesday were published on the Web site of The Lancet: Respiratory Medicine, in an early preview before publication.

根據「電腦網路內容分級處理辦法」修正條文第六條第三款規定，已於網站首頁或各該限制級網頁，依台灣網站分級推廣基金會規定作標示。 台灣網站分級推廣基金會（TICRF）網站：http://www.ticrf.org.tw 《TAIPEI TIMES》 Medigen optimistic over trials From left, Medigen Vaccine Biolog...

Medigen Vaccine Biologics Corp (高端疫苗) yesterday reported positive results from an interim analysis of phase 2 trials for its COVID-19 vaccine, saying that the vaccine demonstrated high seroconversion rates and geometric mean titer (GMT) figures. A seroconversion rate is the percentage of participants in a trial displaying virus-specific immune memory after being given a vaccine, while the GMT measures the level of neutralizing antibody response, Medigen said. The experimental vaccine has a seroconversion rate of 99.8 percent and its GMT was 662 among the participants aged 20 to 89, whi...